Secukinumab may slow structural ankylosing spondylitis progression

LONDON – Long-term treatment with the interleukin 17A inhibitor secukinumab showed suggestive evidence of inhibiting structural progression of spinal disease in 168 patients with ankylosing...
Source: Family Practice News - Category: Primary Care Source Type: news